LEGACY Biotheoretics is developing the technologies, infrastructure, and commercialization strategy necessary to establish the emerging Consumer Biologicals industry. By combining advances in synthetic biology, computational design, artificial intelligence, and scalable biological manufacturing, we are creating a platform capable of supporting an entirely new class of engineered living products. Our mission extends beyond a single innovation as we are building the foundation for a long-term biotechnology enterprise with applications across multiple consumer and commercial markets.

Investor Engagement

Building the Next Frontier of Biotechnology

Why LEGACY?

The biotechnology industry has historically focused on medicine, agriculture, and industrial applications. We believe the next major frontier lies in responsibly engineered living products designed for everyday life. As enabling technologies continue to mature, opportunities that were once considered theoretical are rapidly becoming commercially achievable. LEGACY is positioning itself to become a category-defining company within this emerging space.

A Growing Market Opportunity

Consumer demand for unique, high-value companion experiences continues to expand alongside rapid advances in synthetic biology and artificial intelligence. At the same time, the global exotic companion animal market is projected to grow from approximately $16.4 billion in 2026 to more than $33 billion by 2035, reflecting sustained consumer interest in novel companion animals and the broader ecosystem of products and services that support them.

LEGACY's commercialization strategy is designed to mature alongside these expanding markets, unlocking progressively larger opportunities as our technology platform advances.

$16B+ global exotic companion animal market.
Projected 8%+ CAGR through 2035.
Consumer pet industry exceeding $250B in the U.S.
Bio-manufacturing becoming increasingly cost-effective.
AI dramatically reducing design timelines.

A Platform Designed for Scale

Our approach is built around more than individual products. We are developing proprietary capabilities in biological design, incubation technologies, computational biology, and scalable biological manufacturing that can support multiple future product families, strategic partnerships, licensing opportunities, and adjacent commercial applications.

This platform-first strategy is intended to create durable intellectual property, diversified revenue opportunities, and long-term enterprise value.

Why We Believe This Industry Is Inevitable

Throughout history, technological revolutions have emerged when multiple scientific disciplines reached maturity simultaneously. We believe biotechnology is approaching one of those defining moments. Advances in synthetic biology, artificial intelligence, computational modeling, and scalable biological manufacturing are converging to transform biology from something we merely study into something we can responsibly design, optimize, and commercialize.

The result is the inevitable emergence of a new class of consumer-facing biological technologies with applications that extend far beyond medicine and agriculture. As these enabling technologies continue to mature, products once confined to research laboratories are becoming commercially achievable, opening entirely new markets and redefining how consumers interact with biotechnology. As we say, we want to make biotech as common in households as televisions and toothpaste.

Biology Is Becoming Programmable

Modern genetic engineering has progressed far beyond traditional breeding and basic gene editing. Today's tools increasingly allow biological systems to be designed with greater precision, predictability, and scalability, establishing the technical foundation for an entirely new generation of engineered living products.

Artificial Intelligence Is Accelerating Discovery

Artificial intelligence is fundamentally changing biological research. From genomic analysis and protein modeling to design optimization and predictive simulation, AI is dramatically reducing development timelines while expanding the complexity of biological systems that can be explored. Together, AI and synthetic biology are reshaping what is commercially possible.

Consumer Expectations Continue to Evolve

Consumers increasingly seek products that are personalized, interactive, sustainable, and experience-driven. Just as robotics, smart devices, and artificial intelligence have transformed everyday life, biotechnology is beginning its own transition into consumer markets, creating opportunities for products that combine advanced science with meaningful real-world experiences.

Manufacturing Is Reaching Commercial Scale

Advances in laboratory automation, computational workflows, biological manufacturing, and supporting infrastructure continue to lower barriers to commercialization. These improvements are making sophisticated biological products increasingly practical to develop, manufacture, and distribute while supporting the long-term scalability necessary for sustainable business growth.

Investment Opportunity

LEGACY is currently seeking strategic investors who share our long-term vision for building a new biotechnology category. Current funding will support laboratory infrastructure, research and development, intellectual property expansion, key personnel recruitment, and commercialization activities necessary to establish our foundational technology platform.

As the technologies enabling programmable biology continue to mature, new commercial categories will inevitably emerge. Our objective as a company is not simply to participate in that future, but to help define it by building the scientific platform, commercial strategy, and responsible leadership required to establish the Consumer Biologicals industry.

Our Perspective:

We do not believe this transformation is speculative.

We KNOW it is evolutionary.

Qualified investors interested in confidential materials, executive discussions, or partnership opportunities are invited to contact our leadership team directly by clicking the LEGACY icon or visiting our "Contact Us" page.